MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze NYXH →
    • FindStock Picks / Stock Screener
    • Value · NYXHIntrinsic Value Calculator
    • Invest · NYXHInvestment Case
    • Hold · NYXH5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NYXH

NYXH

Nyxoah S.A.

$0.81
-0.05
 (-6.25%)
Exchange:  NASDAQ
Market Cap:  81.981M
Shares Outstanding:  38.107M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – SpecialtiesView industry performance
   
CEO:  Liam J. Kelly
Full Time Employees:  154
Address: 
Rue Edouard Belin 12
Mont-Saint-Guibert
WA
1435
BE
Website:  https://www.nyxoah.com
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Click to read more…

Revenue Segmentation

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
NYNYXH logoNYXHNyxoah S.A.82.0M——-68.1%
SKSKIN logoSKINSkinHealth Systems Inc.76.7M——2.1%
APAPYX logoAPYXApyx Medical Corporation101.1M——-6.4%
ANANIK logoANIKAnika Therapeutics, Inc.177.2M—11.9-0.4%
LALAB logoLABStandard BioTools Inc.249.1M——-6.6%
BWBWAY logoBWAYBrainsWay Ltd.332.6M34.729.29.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/12 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue4,3484,52110,020
Gross Profit2,6922,9696,326
EBITDA-42,080-51,811-82,901
Operating Income-45,102-58,809-82,942
Net Income-43,212-59,236-90,085

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets124,157158,406118,426.627
Total Liabilities26,13545,15269,342
Total Stockholders Equity98,022113,25449,110.598
Total Debt12,70422,65342,060.240
Cash and Cash Equivalents21,61034,18629,989.763

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-44,778-49,226-67,495.710
Capital Expenditure-10,962-6,072-804.698
Free Cash Flow-55,740-55,298-68,300.409
Net Income-44,657-56,432-90,051.259
Net Change in Cash3,72212,576-130.691

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)259,950.749Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)281,005.397Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)270,190.425Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)92,621.671Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)92,782.519Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)92,699.897Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,192.554Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,319.624Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,254.353Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,811,083.123Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,957,771.363Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,882,423.193Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.030Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.030Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.030Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.799M  ?P/S
 (TTM)
: 
2.5
?Net Income
 (TTM)
: 
-47.695M  ?P/E
 (TTM)
: 
-0.43
?Enterprise Value
 (TTM)
: 
113.166M  ?EV/FCF
 (TTM)
: 
-1.51
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-157.03%  ?ROIC
 (TTM)
: 
-68.12%
?Net Debt
 (TTM)
: 
-53.052M  ?Debt/Equity
 (TTM)
: 
0.79
?P/B
 (TTM)
: 
1.09  ?Current Ratio
 (TTM)
: 
2.19

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates NYXH intrinsic value between $0.38 – $0.49 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate NYXH Intrinsic Value

Common questions about NYXH valuation

Is Nyxoah S.A. (NYXH) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Nyxoah S.A. (NYXH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NYXH a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NYXH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NYXH’s P/E ratio?

You can see NYXH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NYXH?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NYXH a good long-term investment?

Whether NYXH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Nyxoah S.A.

  • Nyxoah S.A. intrinsic value calculatorEstimate what the business is worth
  • Nyxoah S.A. 5-year outlookWhat has to go right, and what could go wrong
NYXH

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-6.25
MarketSnap

Trading Metrics:

Open: 0.84   Previous Close: 0.86
Day Low: 0.8   Day High: 0.84
Year Low: 0.8   Year High: 5.39
Price Avg 50: 1.15   Price Avg 200: 2.22
Volume: 97550   Average Volume: 262480

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Nyxoah SA (NYXH) Q3 2026 Earnings Call Transcript
06-11-2026 14:24
Nyxoah SA (NYXH) Q3 2026 Earnings Call Transcript
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
26-10-2026 17:05
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Nyxoah Appoints Liam Kelly as Chief Executive Officer
28-09-2026 16:30
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah Announces Chief Financial Officer Transition
21-09-2026 16:01
Nyxoah Announces Chief Financial Officer Transition
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
07-09-2026 16:05
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
07-09-2026 16:05
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze NYXH →
    • FindStock Picks / Stock Screener
    • Value · NYXHIntrinsic Value Calculator
    • Invest · NYXHInvestment Case
    • Hold · NYXH5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.